In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
A view from DC: Geolocation enforcement trends include broad lessons for US privacy teams
Notes from the IAPP Canada: Cases show privacy transparency, cooperation matter
Ghost jobs: The phantom hiring trend with data privacy implications
Notes from the IAPP Europe: New EU leadership, new and bigger GDPR complaints and much more news as the year ends
Notes from the Asia-Pacific region: What a week in Australia
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.